Andrew L Feldman

List of Publications by Citations

158 papers	4,725 citations	35 h-index	66 g-index
171 ext. papers	6,268 ext. citations	4.6 avg, IF	5.28 L-index

#	Paper	IF	Citations
158	Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. *Nature Medicine*, **2018**, 24, 679-690	50.5	659
157	ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. *Blood*, **2014**, 124, 1473-80	2.2	294
156	Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. *Blood*, **2011**, 117, 915-9	2.2	223
155	Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. *Journal of the National Cancer Institute Monographs*, **2014**, 2014, 130-44	4.8	199
154	Seroma-associated primary anaplastic large-cell lymphoma adjacent to breast implants: an indolent T-cell lymphoproliferative disorder. *Modern Pathology*, **2008**, 21, 455-63	9.8	169
153	Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. *Blood*, **2012**, 120, 2280-9	2.2	164
152	B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. *Blood*, **2009**, 114, 2149-58	2.2	162
151	Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. *American Journal of Hematology*, **2016**, 91, 1096-1101	7.1	137
150	Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies. *Modern Pathology*, **2011**, 24, 596-605	9.8	127
149	Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis. *American Journal of Surgical Pathology*, **2013**, 37, 1173-81	6.7	125
148	A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. *Lancet Oncology, The*, **2018**, 19, 549-561	21.7	112
147	Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling. *Journal of Pathology*, **2011**, 223, 496-510	9.4	107
146	A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. *Blood*, **2018**, 132, 49-58	2.2	90
145	Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma. *Blood*, **2016**, 128, 1234-45	2.2	77
144	Anaplastic large cell lymphomas: ALK positive, ALK negative, and primary cutaneous. *Advances in Anatomic Pathology*, **2015**, 22, 29-49	5.1	75
143	Morphologic Features of ALK-negative Anaplastic Large Cell Lymphomas With DUSP22 Rearrangements. *American Journal of Surgical Pathology*, **2016**, 40, 36-43	6.7	70
142	and rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. *Blood*, **2017**, 130, 554-557	2.2	68

141	Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma. *Clinical Cancer Research*, **2014**, 20, 2862-72	12.9	68
140	Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms. *Expert Review of Hematology*, **2017**, 10, 239-249	2.8	60
139	Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. *Blood*, **2018**, 132, 544-547	17.2	60
138	PAX5-positive T-cell anaplastic large cell lymphomas associated with extra copies of the PAX5 gene locus. *Modern Pathology*, **2010**, 23, 593-602	9.8	58
137	SVAtools for junction detection of genome-wide chromosomal rearrangements by mate-pair sequencing (MPseq). *Cancer Genetics*, **2018**, 221, 1-18	2.3	57
136	Diagnostic uses of Pax5 immunohistochemistry. *Advances in Anatomic Pathology*, **2007**, 14, 323-34	5.1	53
135	The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-B positive feedback loop in peripheral T-cell lymphoma. *Blood*, **2015**, 125, 3118-27	2.2	47
134	Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry. *Blood*, **2019**, 134, 2159-2170	2.2	45
133	Recurrent fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. *Blood* , **2018**, 131, 2262-2266	2.2	45
132	Novel TRAF1-ALK fusion identified by deep RNA sequencing of anaplastic large cell lymphoma. *Genes Chromosomes and Cancer*, **2013**, 52, 1097-102	5	45
131	Pediatric histiocytic sarcoma clonally related to precursor B-cell acute lymphoblastic leukemia with homozygous deletion of CDKN2A encoding p16INK4A. *Pediatric Blood and Cancer*, **2011**, 56, 307-10	3	45
130	Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with rearrangements. *Blood*, **2018**, 132, 1386-1398	2.2	44
129	ITK/SYK translocation in angioimmunoblastic T-cell lymphoma. *American Journal of Surgical Pathology*, **2013**, 37, 1456-7	6.7	43
128	Mucosal CD30-positive T-cell lymphoproliferations of the head and neck show a clinicopathologic spectrum similar to cutaneous CD30-positive T-cell lymphoproliferative disorders. *Modern Pathology*, **2012**, 25, 983-92	9.8	42
127	Medical history, lifestyle, family history, and occupational risk factors for peripheral T-cell lymphomas: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. *Journal of the National Cancer Institute Monographs*, **2014**, 2014, 66-75	4.8	40
126	A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation. *Blood*, **2009**, 113, 5206-16	2.2	40
125	Incidence of TCR and TCL1 gene translocations and isochromosome 7q in peripheral T-cell lymphomas using fluorescence in situ hybridization. *American Journal of Clinical Pathology*, **2008**, 130, 178-85	1.9	39
124	Copy number variant analysis using genome-wide mate-pair sequencing. *Genes Chromosomes and Cancer*, **2018**, 57, 459-470	5	38

123	International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma. *Journal of Clinical Oncology*, **2017**, 35, 4019-4026	2.2	35
122	Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. *International Journal of Epidemiology*, **2017**, 46, 1753-1754i	7.8	35
121	Lymphoma classification update: B-cell non-Hodgkin lymphomas. *Expert Review of Hematology*, **2017**, 10, 405-415	2.8	32
120	Genetic Landscape and Classification of Peripheral T Cell Lymphomas. *Current Oncology Reports*, **2017**, 19, 28	6.3	32
119	Genetics of anaplastic large cell lymphoma. *Leukemia and Lymphoma*, **2016**, 57, 21-7	1.9	31
118	Expression of p63 protein in anaplastic large cell lymphoma: implications for genetic subtyping. *Human Pathology*, **2017**, 64, 19-27	3.7	31
117	Inferior survival in high-grade B-cell lymphoma with and and/or rearrangements is not associated with gene rearrangements. *Haematologica*, **2018**, 103, 1899-1907	6.6	31
116	Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. *American Journal of Hematology*, **2016**, 91, 179-84	7.1	30
115	t(8;9)(p22;p24)/PCM1-JAK2 activates SOCS2 and SOCS3 via STAT5. *PLoS ONE*, **2013**, 8, e53767	3.7	29
114	Best Practices Guideline for the Pathologic Diagnosis of Breast Implant-Associated Anaplastic Large-Cell Lymphoma. *Journal of Clinical Oncology*, **2020**, 38, 1102-1111	2.2	27
113	Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma. *British Journal of Haematology*, **2019**, 186, e28-e31	4.5	25
112	Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies. *Blood Advances*, **2020**, 4, 1917-1926	7.8	24
111	Recurrent mutations in ALK-negative anaplastic large cell lymphoma. *Blood*, **2019**, 133, 2776-2789	2.2	23
110	STAT3 mutation and its clinical and histopathologic correlation in T-cell large granular lymphocytic leukemia. *Human Pathology*, **2018**, 73, 74-81	3.7	23
109	RVboost: RNA-seq variants prioritization using a boosting method. *Bioinformatics*, **2014**, 30, 3414-6	7.2	21
108	Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. *Blood Cancer Journal*, **2019**, 9, 73	7	19
107	History of autoimmune conditions and lymphoma prognosis. *Blood Cancer Journal*, **2018**, 8, 73	7	19
106	Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma. *Blood*, **2019**, 134, 1289-1297	2.2	19

105	HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. *Cancer Research*, **2018**, 78, 4086-4096	10.1	18
104	SIRP□expression delineates subsets of intratumoral monocyte/macrophages with different functional and prognostic impact in follicular lymphoma. *Blood Cancer Journal*, **2019**, 9, 84	7	16
103	A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma. *Blood*, **2019**, 134, 467-467	2.2	16
102	Loss of TNFAIP3 enhances MYD88-driven signaling in non-Hodgkin lymphoma. *Blood Cancer Journal* , **2018**, 8, 97	7	16
101	Adult systemic anaplastic large-cell lymphoma: recommendations for diagnosis and management. *Expert Review of Hematology*, **2016**, 9, 137-50	2.8	15
100	Genetics of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). *Aesthetic Surgery Journal*, **2019**, 39, S14-S20	2.4	15
99	Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma. *Blood Cancer Journal*, **2018**, 8, 110	7	15
98	Human Pegivirus infection and lymphoma risk and prognosis: a North American study. *British Journal of Haematology*, **2018**, 182, 644-653	4.5	15
97	ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients. *Haematologica*, **2019**, 104, e562-e565	6.6	14
96	Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression. *Haematologica*, **2018**, 103, 297-303	6.6	14
95	Retinoic acid receptor alpha drives cell cycle progression and is associated with increased sensitivity to retinoids in T-cell lymphoma. *Oncotarget*, **2017**, 8, 26245-26255	3.3	13
94	Comment on: Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma, by Yoo et al. *Haematologica*, **2016**, 101, e269-70	6.6	13
93	Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis. *Clinical Infectious Diseases*, **2020**, 71, 1221-1228	11.6	12
92	MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma. *Haematologica*, **2021**, 106, 2682-2693	6.6	12
91	Cyclin D1 expression in peripheral T-cell lymphomas. *Modern Pathology*, **2016**, 29, 1306-1312	9.8	12
90	Associations between elevated pre-treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphoma. *American Journal of Hematology*, **2017**, 92, 752-758	7.1	11
89	Chromosomal rearrangements and copy number abnormalities of TP63 correlate with p63 protein expression in lung adenocarcinoma. *Modern Pathology*, **2015**, 28, 359-66	9.8	10
88	Genetic alterations affecting GTPases and T-cell receptor signaling in peripheral T-cell lymphomas. *Small GTPases*, **2019**, 10, 33-39	2.7	10

87	Molecular profiling reveals a hypoxia signature in breast implant-associated anaplastic large cell lymphoma. *Haematologica*, **2021**, 106, 1714-1724	6.6	10
86	The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas. *American Journal of Hematology*, **2019**, 94, 658-666	7.1	9
85	Cutaneous lesions of angioimmunoblastic T-cell lymphoma: Clinical, pathological, and immunophenotypic features. *Journal of Cutaneous Pathology*, **2019**, 46, 637-644	1.7	9
84	Update on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms. *Expert Review of Hematology*, **2019**, 12, 833-843	2.8	9
83	Prevalence, clinical characteristics and prognosis of EBV-positive follicular lymphoma. *American Journal of Hematology*, **2019**, 94, E62-E64	7.1	9
82	Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. *Leukemia*, **2021**, 35, 522-533	10.7	9
81	Coactivation of NF-B and Notch signaling is sufficient to induce B-cell transformation and enables B-myeloid conversion. *Blood*, **2020**, 135, 108-120	2.2	8
80	Expression of the chemokine receptor gene, CCR8, is associated With DUSP22 rearrangements in anaplastic large cell lymphoma. *Applied Immunohistochemistry and Molecular Morphology*, **2015**, 23, 580-9	1.9	8
79	Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenstrm macroglobulinemia. *Nature Communications*, **2018**, 9, 4182	17.4	8
78	The association of physical activity before and after lymphoma diagnosis with survival outcomes. *American Journal of Hematology*, **2018**, 93, 1543-1550	7.1	8
77	PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter Transformation: An Updated Report from a Phase 2 Trial (MC1485). *Blood*, **2016**, 128, 4392-4392	2.2	7
76	Targeting epigenetic regulators in the treatment of T-cell lymphoma. *Expert Review of Hematology*, **2020**, 13, 127-139	2.8	7
75	Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas. *British Journal of Haematology*, **2019**, 186, e24-e27	4.5	6
74	In situ neoplasia in lymph node pathology. *Seminars in Diagnostic Pathology*, **2018**, 35, 76-83	4.3	6
73	The Impact of Upfront Autologous Transplant on the Survival of Adult Patients with ALCL and PTCL-NOS According to Their ALK, DUSP22 and TP63 Gene Rearrangement Status - a Joined Nordic Lymphoma Group and Mayo Clinic Analysis. *Blood*, **2017**, 130, 822-822	2.2	6
72	Epstein-Barr-virus-positive large B-cell lymphoma associated with breast implants: an analysis of eight patients suggesting a possible pathogenetic relationship. *Modern Pathology*, **2021**, 34, 2154-2167	9.8	6
71	"Double-hit" of DUSP22 and TP63 rearrangements in anaplastic large cell lymphoma, ALK-negative. *Blood*, **2020**, 135, 700	2.2	6
70	Accuracy of 18-F FDG PET/CT to detect bone marrow clearance in patients with peripheral T-cell lymphoma - tissue remains the issue. *Leukemia and Lymphoma*, **2017**, 58, 2342-2348	1.9	5

69	Clonal Relationships Between Malignant Lymphomas and Histiocytic/Dendritic Cell Tumors. *Surgical Pathology Clinics*, **2013**, 6, 619-29	3.9	5
68	Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. *Blood Cancer Journal*, **2021**, 11, 130	7	5
67	Time from Diagnosis to Initiation of Treatment of DLBCL and Implication for Potential Selection Bias in Clinical Trials. *Blood*, **2016**, 128, 3034-3034	2.2	4
66	Secondary cutaneous involvement by systemic anaplastic lymphoma kinase-negative anaplastic large-cell lymphoma with 6p25.3 rearrangement. *Histopathology*, **2015**, 67, 932-5	7.3	3
65	The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States. *Blood*, **2018**, 132, 1702-1702	2.2	3
64	Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL). *Blood*, **2019**, 134, 69-69	2.2	3
63	Syk Tyrosine Kinase Is Overexpressed in the Majority of Peripheral T- and NK-Cell Lymphomas, and Represents a Potential Therapeutic Target.. *Blood*, **2007**, 110, 690-690	2.2	3
62	In-Vivo Activation Of STAT3 In Angioimmunoblastic T Cell Lymphoma, PTCL Not Otherwise Specified, and ALK Negative Anaplastic Large Cell Lymphoma: Implications For Therapy. *Blood*, **2013**, 122, 844-844	2.2	3
61	Mutations Targeting the ErbB Pathway and MSC in Peripheral T-Cell Lymphoma. *Blood*, **2015**, 126, 2681-2681	2.2	3
60	Striking Association of Lymphoid Enhancing Factor (LEF1) Overexpression and DUSP22 Rearrangements in Anaplastic Large Cell Lymphoma. *American Journal of Surgical Pathology*, **2021**, 45, 550-557	6.7	3
59	Clinical laboratory validation of the MCL35 assay for molecular risk stratification of mantle cell lymphoma. *Journal of Hematopathology*, **2020**, 13, 231-238	0.4	3
58	Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy. *Clinical Epidemiology*, **2019**, 11, 987-996	5.9	3
57	Fluorescence in-situ hybridisation for TP63 rearrangements in T cell lymphomas: single-site experience of 470 patients and implications for clinical testing. *Histopathology*, **2020**, 76, 481-485	7.3	3
56	Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma. *Clinical Cancer Research*, **2021**, 27, 6039-6053	12.9	3
55	Prognostic Impact of Morphology, MYC Gene Partner and BCL2/BCL6 Translocation Status in "High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements". *Blood*, **2016**, 128, 1750-1750	2.2	2
54	Targetability of STAT3-JAK2 fusions: implications for T-cell lymphoproliferative disorders of the gastrointestinal tract. *Leukemia*, **2020**, 34, 1467-1471	10.7	2
53	American Registry of Pathology Expert Opinions: Recommendations for the diagnostic workup of mature T cell neoplasms. *Annals of Diagnostic Pathology*, **2020**, 49, 151623	2.2	2
52	How I Diagnose Anaplastic Large Cell Lymphoma. *American Journal of Clinical Pathology*, **2021**, 155, 479-497	1.9	2

51	Host genetic variation in tumor necrosis factor and nuclear factor-B pathways and overall survival in mantle cell lymphoma: A discovery and replication study. *American Journal of Hematology*, **2019**, 94, E153-E155	7.1	1
50	Exuberant nodal proliferation of mature plasmacytoid dendritic cells in a patient with chronic myelomonocytic leukemia. *Blood*, **2017**, 130, 1387	2.2	1
49	ALK-Negative Anaplastic Large Cell Lymphomas with 6p25.3 Translocations Show a Histone-Modifying Gene Expression Signature. *Blood*, **2011**, 118, 88-88	2.2	1
48	Treatment and Clinical Outcomes of High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements (Double Hit/Triple Hit Lymphomas). *Blood*, **2016**, 128, 155-155	2.2	1
47	Similar Phenotypes Demonstrated upon Initial Diagnosis and at Time of Recurrence in Relapsed DLBCL. *Blood*, **2016**, 128, 5299-5299	2.2	1
46	Event-Free Survival at 24 Months (EFS24) Becomes an Important Clinical Endpoint in Newly Diagnosed Mantle Cell Lymphoma in the New Era. *Blood*, **2021**, 138, 2429-2429	2.2	1
45	The Level of Physical Activity before and after Lymphoma Diagnosis Impacts Overall and Lymphoma-Specific Survival. *Blood*, **2017**, 130, 914-914	2.2	1
44	Prevalence and the Impact of Hypogammaglobulinemia in Newly Diagnosed, Untreated Diffuse Large B Cell Lymphoma. *Blood*, **2019**, 134, 1604-1604	2.2	1
43	Novel Mutations in NOTCH and Altered Wnt/Catenin Pathway Indicate a Role of Embryonic Signals in the Pathogenesis of T-Cell Prolymphocytic Leukemia. *Blood*, **2016**, 128, 4103-4103	2.2	1
42	Massively Parallel Mate Pair DNA Library Sequencing for Translocation Discovery: Recurrent t(6;7)(p25.3;q32.3) Translocations In ALK-Negative Anaplastic Large Cell Lymphomas. *Blood*, **2010**, 116, 633-633	2.2	1
41	A Genome-Wide Association Study (GWAS) Of Event-Free Survival In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With Rituximab and Anthracycline-Based Chemotherapy: A Lysa and Iowa/Mayo Clinic SPORE Multistage Study. *Blood*, **2013**, 122, 76-76	2.2	1
40	PD-L1 expression in anaplastic large cell lymphoma. *Modern Pathology*, **2020**, 33, 1232-1233	9.8	1
39	Reply to M. Romero et al. *Journal of Clinical Oncology*, **2020**, 38, 2819-2820	2.2	1
38	Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair. *Blood*, **2021**, 137, 513-523	2.2	1
37	Genetic profiling and biomarkers in peripheral T-cell lymphomas: current role in the diagnostic work-up. *Modern Pathology*, **2021**,	9.8	1
36	Nodular Lymphocyte Predominant Hodgkin Lymphoma of the Ileum. *Case Reports in Pathology*, **2017**, 2017, 5981013	0.9	0
35	Describing Treatment of Primary Mediastinal Large B Cell Lymphoma Using Rigorously Defined Molecular Classification: A Retrospective Analysis. *Blood*, **2020**, 136, 35-36	2.2	0
34	Clonal Somatic Mutations Are a Biomarker for Inferior Prognosis in Diffuse Large B-Cell Lymphoma. *Blood*, **2020**, 136, 26-27	2.2	0

33	Clinical Validation of MCL35 in Mantle Cell Lymphoma Patients ≥65 Years Receiving Bendamustine-Rituximab. *Blood*, **2021**, 138, 3517-3517	2.2	0
32	The Genomic Landscape of Plasmablastic Lymphoma (PBL) - an L.L.M.P.P. Project. *Blood*, **2021**, 138, 1326-1326	2.2	0
31	Case Report: Multiple Chromosomal Translocations Including Novel CIITA-CREBBP Fusion and Mutations in a Follicular Lymphoma. *Frontiers in Oncology*, **2021**, 11, 620435	5.3	0
30	Body mass index and survival of patients with lymphoma. *Leukemia and Lymphoma*, **2021**, 62, 2671-2678	1.9	0
29	CA9 expression in breast implant-associated anaplastic large cell lymphoma presenting in a lymph node.. *Histopathology*, **2022**,	7.3	0
28	PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts.. *Blood Cancer Journal*, **2022**, 12, 78	7	0
27	RNAseq identification of FISH-cryptic BCL6::TP63 rearrangement in ALK-negative anaplastic large cell lymphoma.. *Histopathology*, **2022**,	7.3	0
26	Educational Case: ALK-Negative Anaplastic Large Cell Lymphoma. *Academic Pathology*, **2020**, 7, 2374289520901813	1.3	
25	High-Dimensional and Single-Cell Transcriptome Analysis of AITL Tumor Microenvironment Reveals Gross Expansion of Novel Dysfunctional CD8+ T Cell Populations, Global Shift in B Cell Phenotypes. *Blood*, **2020**, 136, 42-43	2.2	
24	Body Mass Index and Survival of Patients with Lymphoma. *Blood*, **2020**, 136, 2-3	2.2	
23	Salicylates Potentiate and Broaden CRM1 Inhibitor Anti-Tumor Activity Via S-Phase Arrest and Impaired DNA-Damage Repair. *Blood*, **2020**, 136, 17-18	2.2	
22	Causes of Death in Non-Follicular Indolent B-Cell Lymphoma in the Rituximab Era. *Blood*, **2020**, 136, 36-37	2.2	
21	High Dimensional Tissue-Based Spatial Analysis of the Tumor Microenvironment of Follicular Lymphoma Reveals Unique Immune Niches inside Malignant Follicles. *Blood*, **2020**, 136, 17-18	2.2	
20	Striking Association of Lymphoid Enhancing Factor (LEF1) Overexpression and DUSP22 rearrangements in Anaplastic Large Cell Lymphoma. *Blood*, **2020**, 136, 22-23	2.2	
19	Beyond Mortality: Health-Related Quality of Life in Adolescent and Young Adult Patients with Lymphoma: A Longitudinal Study. *Blood*, **2020**, 136, 7-8	2.2	
18	Short Diagnosis to Treatment Interval (DTI) Is Associated with Inferior Outcome in Newly Diagnosed Patients with Mantle Cell Lymphoma, a MER/LEO and Alliance Collaboration. *Blood*, **2018**, 132, 2878-2878	2.2	
17	Clinical and Quality of Life Predictors of Failure to Achieve Event Free Survival at 24 Months in Patients Aged 70 Years and Older with Diffuse Large B-Cell Lymphoma. *Blood*, **2018**, 132, 3579-3579	2.2	
16	Patterns of Care and Outcomes in Mantle Cell Lymphoma in the Modern Immunochemotherapy Era. *Blood*, **2018**, 132, 4140-4140	2.2	

15	Malignant T-Cells and Normal Intratumoral T-Cells Have Similar Expression of Immune Checkpoint Molecules in Angioimmunoblastic T-Cell Lymphoma. *Blood*, **2019**, 134, 1517-1517	2.2
14	Genomic Analysis of R2CHOP-Treated DLBCL Reveals a High-Risk Population Driven By Inflammatory Pathways. *Blood*, **2019**, 134, 1480-1480	2.2
13	An International Assessment of Event-Free Survival at 24 Months (EFS24) and Subsequent Survival in Peripheral T-Cell Lymphoma. *Blood*, **2016**, 128, 920-920	2.2
12	No Association of EBV or Immunosuppression Status with Outcomes in US Patients with Diffuse Large B-Cell Lymphoma Treated in the Immunochemotherapy Era. *Blood*, **2016**, 128, 107-107	2.2
11	Whole-Exome Analysis Reveals Novel Somatic Genomic Alterations Associated with Cell of Origin in Diffuse Large B-Cell Lymphoma. *Blood*, **2016**, 128, 2935-2935	2.2
10	Retinoic Acid Receptor Alpha Expression Drives Cell-Cycle Progression and Is Associated with Increased Sensitivity to Retinoids in Peripheral T-Cell Lymphoma. *Blood*, **2016**, 128, 1749-1749	2.2
9	Expression of Interferon Regulatory Factor-4 (IRF4/MUM1) Is Associated with Inferior Overall Survival In Peripheral T-Cell Lymphoma. *Blood*, **2010**, 116, 140-140	2.2
8	UCH-L1 Is a Novel Regulator of mTOR Signaling That May Predict a Poor Response to mTOR Inhibition in Patients with B-Cell Lymphoma,. *Blood*, **2011**, 118, 3691-3691	2.2
7	T(8;9)(p22;p24)/PCM1-JAK2 Activates SOCS2 and SOCS3 Via STAT5. *Blood*, **2012**, 120, 1567-1567	2.2
6	CXCR5 Polymorphisms in Non-Hodgkin Lymphoma (NHL) Risk and Prognosis.. *Blood*, **2012**, 120, 2702-2702	2.2
5	Deep Proteomic Profiling Predicts Differential Chemosensitivity In Anaplastic Large Cell Lymphoma Cell Lines. *Blood*, **2013**, 122, 1670-1670	2.2
4	Comparison Of Single Nucleotide Mutations (SNVs) and Copy Number Variants (CNVs) Detection In Formalin Fixed Paraffin Embedded (FFPE) and Paired Frozen Tumor Tissues Using Target Capture and Sequencing Approach. *Blood*, **2013**, 122, 1784-1784	2.2
3	GATA-3 Expression Promotes IL-10 Production, Alternative Macrophage Polarization, and Identifies a Subset Of High-Risk PTCL, NOS. *Blood*, **2013**, 122, 841-841	2.2
2	Chromosomal Junction Detection from Whole-Genome Sequencing on Formalin-Fixed, Paraffin-Embedded Tumors. *Journal of Molecular Diagnostics*, **2021**, 23, 375-388	5.1
1	The Spectrum of Anaplastic Large-cell Lymphoma **2021**, 129-144	